VALIANTLABPharmaceuticals
Valiant Laboratories Ltd — Cash Flow Statement
₹51.62
-5.74%
Valiant Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | 1.31 Cr | 1.89 Cr | 56.05 Cr | 2.25 Cr | — |
| Taxes Refund Paid | 2.47 Cr | 0.98 Cr | -8.80 Cr | -14.47 Cr | — |
| Change In Working Capital | -3.93 Cr | -0.37 Cr | 25.16 Cr | -28.05 Cr | — |
| Change In Other Current Liabilities | 0.02 Cr | -1.89 Cr | -3.00 Cr | 16.37 Cr | — |
| Change In Other Current Assets | 2.38 Cr | -23.02 Cr | -4.13 Cr | -1.75 Cr | — |
| Change In Payable | 14.79 Cr | -21.37 Cr | 8.02 Cr | 35.34 Cr | — |
| Change In Inventory | 6.03 Cr | 3.03 Cr | 2.76 Cr | -9.73 Cr | — |
| Change In Receivables | -27.27 Cr | 42.88 Cr | 21.51 Cr | -68.27 Cr | — |
| Other Non Cash Items | 0.18 Cr | 0.08 Cr | -70000.00 | 0.61 Cr | — |
| Provisionand Write Offof Assets | 1.01 Cr | 0.00 | — | — | — |
| Depreciation And Amortization | 2.09 Cr | 1.97 Cr | 1.56 Cr | 2.49 Cr | — |
| Depreciation | 2.09 Cr | 1.97 Cr | 1.56 Cr | 2.49 Cr | — |
| Pension And Employee Benefit Expense | 0.06 Cr | 0.00 | — | — | — |
| Gain Loss On Investment Securities | 0.93 Cr | — | — | — | — |
| Net Foreign Currency Exchange Gain Loss | 0.01 Cr | 0.00 | 0.00 | — | — |
| Net Income From Continuing Operations | -1.51 Cr | -0.77 Cr | 38.14 Cr | 41.70 Cr | — |
| Free Cash Flow | -112.54 Cr | -43.98 Cr | 18.37 Cr | -4.63 Cr | — |
| Capital Expenditure | -113.85 Cr | -45.87 Cr | -37.68 Cr | -6.88 Cr | — |
| End Cash Position | 4.92 Cr | 11.72 Cr | 1.26 Cr | 0.13 Cr | — |
| Other Cash Adjustment Outside Changein Cash | -1000.00 | 1000.00 | — | — | -10000.00 |
| Beginning Cash Position | 11.72 Cr | 1.26 Cr | 1.31 Cr | 3.94 Cr | — |
| Changes In Cash | -6.80 Cr | 10.46 Cr | -0.05 Cr | -3.81 Cr | — |
| Financing Cash Flow | 44.65 Cr | 152.45 Cr | -0.93 Cr | 6.18 Cr | — |
| Net Other Financing Charges | 1000.00 | — | — | — | — |
| Interest Paid Cff | -0.18 Cr | -0.08 Cr | -0.03 Cr | -0.61 Cr | — |
| Net Common Stock Issuance | 0.00 | 135.88 Cr | 0.00 | 48.90 Cr | — |
| Net Issuance Payments Of Debt | 45.15 Cr | 16.65 Cr | -1.28 Cr | -42.07 Cr | — |
| Net Short Term Debt Issuance | 15.47 Cr | 1.39 Cr | -1.28 Cr | — | — |
| Net Long Term Debt Issuance | 29.69 Cr | 15.26 Cr | 0.00 | -42.07 Cr | — |
| Investing Cash Flow | -52.77 Cr | -143.88 Cr | -55.17 Cr | -12.24 Cr | — |
| Net Other Investing Changes | 23.42 Cr | -94.41 Cr | 16.10 Cr | -5.00 Cr | — |
| Net Investment Purchase And Sale | 37.61 Cr | -3.59 Cr | -33.62 Cr | -0.40 Cr | — |
| Sale Of Investment | 37.61 Cr | 0.00 | — | — | — |
| Purchase Of Investment | 0.00 | -3.59 Cr | -33.62 Cr | -0.40 Cr | — |
| Net PPE Purchase And Sale | -113.80 Cr | -45.87 Cr | -37.68 Cr | -6.84 Cr | — |
| Sale Of PPE | 0.06 Cr | 0.00 | — | 0.04 Cr | 0.00 |
| Purchase Of PPE | -113.85 Cr | -45.87 Cr | -37.68 Cr | -6.88 Cr | — |
| Interest Received Cfi | — | 0.00 | 0.03 Cr | — | — |
| Gain Loss On Sale Of PPE | — | — | — | 0.04 Cr | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Valiant Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.